Fallopian Tube Cancer Clinical Trials

A listing of 31 Fallopian Tube Cancer clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Conditions

Fallopian Tube Cancer

1 - 12 of 31

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

There are currently 31 active clinical trials seeking participants for Fallopian Tube Cancer research studies. The states with the highest number of trials for Fallopian Tube Cancer participants are California, England, Texas and New York.

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Studying an Investigational Virus Vaccine

Recruiting

The main objectives of this study are to assess the safety and effectiveness of an investigational vaccine aimed at preventing norovirus, commonly known as the stomach flu. Participants will be randomly assigned to receive either the investigational vaccine or a placebo. Should you express interest, you will be contacted directly by the research site, which will provide further details and answer any questions you may have about study requirements, risks/benefits, and any compensation.

Conditions:

Healthy

Interested in vaccine studies

All Conditions

Preventative Trials

Learn More

Featured Trial

Major Depressive Disorder Clinical Study

Recruiting

Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.

Conditions:

Major Depressive Disorder

Major Depression

Major Depressive Episode

Major Depressive Disorder (MDD)

Major Depressive Disorders

Learn More

Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Ovarian, Fallopian Tube, or Peritoneal Cancer (GLORIOSA)

NCT05445778

Recruiting

GLORIOSA is a Phase 3 multicenter, open label study designed to evaluate the safety and efficacy of mirvetuximab Soravtansine as maintenance therapy in participants with platinum-sensitive ovarian, primary peritoneal or fallopian tube cancers with high folate receptor-alpha (FRα) expression.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/18/2025

Locations: USA Mitchell Cancer Institute, Mobile, Alabama +274 locations

USA Mitchell Cancer Institute, Mobile, Alabama

Honor Health Cancer Care, Biltmore, 2222 E. Highland Ave, #400, Phoenix, Arizona

John Muir Health, Concord, California

City of Hope, Irvine, California

Kaiser Permanente Irvine Medical Center, 6650 Alton Pkwy, Irvine, California

UC San Diego Health - Moores Cancer Center, La Jolla, California

Kaiser Permanente Los Angeles Medical Center, 4950 Sunset Blvd., 6th Floor, Los Angeles, California

UCI Health- Chao Family Comprehensive Cancer Center, Orange, California

Stanford University, Palo Alto, California

Kaiser Permanente Riverside Medical Center, 10800 Magnolia Ave, Riverside, California

Kaiser Permanente Zion Medical Center, 4647 Zion Ave, San Diego, California

Kaiser Permanente San Marcos Medical Offices, 400 Craven Road, San Marcos, California

Olive View UCLA Medical Center Inpatient Pharmacy, 14445 Olive View Dr, Rm 1C101, Sylmar, California

Broward Health Medical Center, Fort Lauderdale, Florida

Regional Cancer Center/ Florida Gynecologic Oncology, Fort Myers, Florida

Baptist MD Anderson Cancer Center, Jacksonville, Florida

Mount Sinai Comprehensive Cancer Center, Miami, Florida

Sarasota Memorial Health Care System, Sarasota, Florida

Northside Hospital, Atlanta, Georgia

Rush University Medical Center, 1725 West Harrison Street, Chicago, Illinois

University of Chicago Medicine, 5841 S Maryland Ave, MC 2115, Chicago, Illinois

Indiana University, Indianapolis, Indiana

St Vincent Gynecologic Oncology, Indianapolis, Indiana

University of Iowa Health Care, Iowa City, Iowa

University of Kansas Cancer Center, Westwood, Kansas

Baptist Health Lexington, Lexington, Kentucky

University of Kentucky, Lexington, Kentucky

LSUHSC, New Orleans, Louisiana

Ochsner Clinic Foundation, New Orleans, Louisiana

Maine Medical Center, Scarborough, Maine

Greater Baltimore Medical Center, Baltimore, Maryland

Sinai Hospital of Baltimore, Inc., Baltimore, Maryland

Johns Hopkins Medical Institute, Baltimore, Maryland

Tufts Medical Center, Boston, Massachusetts

Baystate Gynecologic Oncology - Tolosky Center, Springfield, Massachusetts

Corewell Health, Grand Rapids, Michigan

Minnesota Oncology Hematology, P.A. (USOR), Maplewood, Minnesota

Nebraska Methodist Hospital, Omaha, Nebraska

Center of Hope at Renown Medical Center, Reno, Nevada

Dartmouth Hitchcock Medical, One Medical Center Drive, Lebanon, New Hampshire

John Theurer Cancer Center, University Medical Center, 92 Second Street, Hackensack, New Jersey

The Valley Hospital -Luckow Pavilion, Paramus, New Jersey

Holy Name Medical Center, Teaneck, New Jersey

New York Oncology Hematology, P.C. (USOR), Albany, New York

Perlmutter Cancer Center at NYU Langone Health-Long Island, Mineola, New York

Perlmutter Cancer Center at NYU Langone Health, New York, New York

Mount Sinai Hospital, New York, New York

Northwell Health Cancer Institute, New York, New York

Womens Cancer Care Associates, New York, New York

UNC-Chapel Hill, Chapel Hill, North Carolina

Duke Cancer Center, Durham, North Carolina

University of Cincinnati, Cincinnati, Ohio

Ohio State University, Columbus, Ohio

Kettering Health, Kettering, Ohio

OU Health Stephenson Cancer Center, Oklahoma City, Oklahoma

Oklahoma Cancer Specialists and Research Institute, Tulsa, Oklahoma

Willamette Valley Cancer Institute and Research Center (USOR), Eugene, Oregon

Northwest Cancer Specialists, P.C. (USOR), Portland, Oregon

OHSU Center for Health & Healing, Building 2 (CHH2), 3485 S Bond Ave, Portland, Oregon

Magee Women's Hospital - UPMC, Pittsburgh, Pennsylvania

Allegheny Health Network, Pittsburgh, Pennsylvania

Sidney Kimmel Cancer Center Asplundh Cancer Pavilion, Willow Grove, Pennsylvania

Sanford Gynecologic Oncology, 1309 W. 17th street, Sioux Falls, South Dakota

The West Clinic, PLLC dba West Cancer Center, Germantown, Tennessee

Texas Oncology, P.A. (USOR), Austin, Texas

Texas Oncology - DFWW (USOR), Bedford, Texas

Texas Oncology-Dallas Presbyterian Hospital (USOR), Dallas, Texas

Texas Oncology (USOR), Fort Worth, Texas

Texas Oncology - San Antonio (USOR), San Antonio, Texas

University of Virginia, Charlottesville, Virginia

Virginia Oncology Associates (USOR), Norfolk, Virginia

Virginia Commonwealth University (VCU)- Massey Comprehensive Cancer Center, Richmond, Virginia

Swedish Cancer Institute, Seattle, Washington

Instituto Alexander Fleming, Caba, Not set

Hospital Italiano de Buenos Aires, Caba, Not set

Instituto de Oncologia Angel Roffo, Caba, Not set

Hospital Italiano de Cordoba, Córdoba, Not set

Sanatorio de la Mujer, Rosario, Not set

Isis Centro Especializado, Santa Fe, Not set

Westmead Hospital, Westmead, New South Wales

Gold Coast University Hospital, Southport, Queensland

Grampians Health Service, Ballarat, Victoria

Cabrini Health, Brighton, Victoria

Monash Health, Clayton, Victoria

Peter Maccallum Cancer Centre, Melbourne, Victoria

Epworth Health, Richmond, Victoria

Bendat Family Comprehensive Cancer Centre St John of God - Subiaco Hospital, Subiaco, Not set

Imeldaziekenhuis, Apotheek Klinische Studies, Imeldalaan 9 Centraal Magazjin, Bonheiden, Not set

Cliniques Universitaires St-Luc Woluwe-Saint-Lambert, Brussel, Not set

GHDC Grand Hôpital de Charleroi, Site Notre-Dame, Grand Rue 3, Charleroi, Not set

AZ Sint Lucas Gent, Groenebriel 1, Gent, Not set

UZ Leuven, Apotheek Klinische studies, Herestraat, 49, Leuven, Not set

CHU UCL Namur - Site Sainte-Elisabeth, Route (Road) 471 Place Louise Godin 15, Oncology Day Hospital, 3rd Floor, Namur, Not set

AZ Delta apotheek, Tav Klinische studies, Kwadestraat 78, Roeselare, Not set

Fundacao Pio XII - Hospital de Amor de Barretos, Barretos, Not set

Oncocentro, Belo Horizonte, Not set

Clinica Oncolog, Cuiabá, Not set

Instituo de Ensino e Pesquisa (IEP) Oncocentro, Fortaleza, Not set

Catarina Pesquisa Clinica, Itajaí, Not set

Hospital Moinhos de Vento, Porto Alegre, Not set

Santa Casa Misericordia Porto Alegre, Porto Alegre, Not set

IMIP, Recife, Not set

Instituto Nacional de Cancer, Rio De Janeiro, Not set

Instituto COI, Rio De Janeiro, Not set

Hospital Santa Izabel, Salvador, Not set

Ensino e Terapia de Inovacao Clinica AMO-ETICA, Salvador, Not set

BP A Beneficencia Portuguesa de Sao Paulo, São Paulo, Not set

Dasa, São Paulo, Not set

Ac camargo Cancer center, São Paulo, Not set

Complex Oncology Center - Shumen Ltd, Shumen, Not set

Comprehensive Cancer Center - Vratsa, Vratsa, Not set

Tom Baker Cancer Centre, Alberta Health Services, Calgary, Alberta

University of Alberta - Cross Cancer Institute (CCI), Edmonton, Alberta

BC Cancer Surrey, Surrey, British Columbia

BC Cancer - Vancouver, Vancouver, British Columbia

Juravinski Cancer Centre, Hamilton, Ontario

Kinston Health Sciences Center - KGH Site, Kingston, Ontario

The Ottawa Hospital Cancer Centre, Ottawa, Ontario

Princess Margaret Cancer Centre, Toronto, Ontario

Universite de Montreal - Hopital Maisonneuve-Rosemont (HMR), Montreal, Quebec

Centre Hospitalier de L'Universite de Montreal - Centre de Recherche, Montreal, Quebec

McGill University Health Centre, Montreal, Quebec

CHUS - Hôpital Fleurimont, Sherbrooke, Quebec

Bejing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, Not set

Bejing Cancer Hospital, Beijing, Not set

The First Affiliated Hospital of Bengbu Medical University, Bengbu, Not set

The First Hospital of Jilin University, Changchun, Not set

Hunan Cancer Hospital, Changsha, Not set

West China Second University Hospital, Sichuan University, Chengdu, Not set

Fujian Cancer Hospital, Fuzhou, Not set

The First Affliliated Hospital, Sun Yat-sen University, Guangzhou, Not set

Sun Yat-Sen Memorial Hospital,Sun Yat-sen University, Guangzhou, Not set

Zhejiang Cancer Hospital, Hangzhou, Not set

Woman's Hospial School of Medicine ZheJiang University, Hangzhou, Not set

Harbin medical university Cancer Hospital, Harbin, Not set

Cancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan, Not set

Qilu Hospital of Shandong University, Jinan, Not set

Yunnan Cancer Hospital (The Third Affiliated Hospital of Kunming Medical University ), Kunming, Not set

Linyi Cancer Hospital, Linyi, Not set

Guangxi Cancer Hospital (Guangxi Medical University Cancer Hospital), Naning, Not set

Fudan University shanghai Cancer Center, Shanghai, Not set

Liaoning Cancer Hospital, Shenyang, Not set

Shanxi Cancer Hospital, Taiyuan, Not set

Tianjin Medical University Cancer Institute&Hospital, Tianjin, Not set

Cancer Hospital Affiliated to Xinjiang Medical University, Urumqi, Not set

Hubei Cancer Hospital, Wuhan, Not set

The First Affiliated Hospital of Xi'an Jiaotong University, Xian, Not set

The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Not set

Henan Cancer Hospital, Zhengzhou, Not set

University Hospital Brno, Brno, Not set

Nemocnice AGEL Nový Jicín a.s., Nový Jicín, Not set

University Hospital Ostrava, Ostrava Poruba, Not set

General University Hospital in Prague, Prague, Not set

Onkologisk Afd, Aalborg Universitets hospital, Aalborg, Not set

Rigshospitalet (Copenhagen University Hospital), Copenhagen, Not set

Kuopio University Hospital, Kuopio, Not set

Oulu University hospital, Oulu, Not set

Turku University Hospital, Turku, Not set

Institut de cancérologie et d'imagerie (ICI) CHU BREST, Brest, Not set

CHU Dijon, Dijon, Not set

Centre Leon Berard, Lyon, Not set

Hôpital Timone, Marseille, Not set

Institut Curie, Paris, Not set

ICANS, Strasbourg, Not set

Studiengesellschaft Onkologie Bielefeld, Bielefeld, Not set

Universitaetsklinikum Bonn, Bonn, Not set

Klinikum Dortmund, Dortmund, Not set

Universitaetsklinikum Carl Gustav Carus, Dresden, Not set

Universitaetsklinik Erlangen, Erlangen, Not set

Universitaetsklinikum Essen, Essen, Not set

KEM Evang. Kliniken Essen-Mitte, Essen, Not set

Klinikum Esslingen GmbH, Esslingen, Not set

UKGM Giessen, Giesen, Not set

Universitaetsklinikum Hamburg-Eppendorf, Hamburg, Not set

Mammazentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Not set

Universitaetsklinikum Heidelberg, Heidelberg, Not set

Klinikum Kassel, Kassel, Not set

Universitätsmedizin Mainz Frauenklinik, Mainz, Not set

LMU Klinikum Großhadern, Munich, Not set

Alexandra Hospital, Athens, Not set

Aretaieio Hospital, Athens, Not set

IASO Hospital, Athens, Not set

Hygeia Hospital, Maroúsi, Not set

St. Luke's Hospital S.A., Thessaloníki, Not set

Cork University Hospital, Cork, Not set

Bon Secours, Cork, Not set

Beaumont Hospital, Dublin, Not set

St. James's Hospital, Dublin, Not set

University Hospital Galway, Galway, Not set

Sligo University Hospital, Sligo, Not set

University Hospital Waterford, Waterford, Not set

Carmel Medical Centre, Haifa, Not set

Wolfson Medical Centre, Holon, Not set

Shaare Zedek Medical Centre, Jerusalem, Not set

Hadassah Medical Ctr. Ein Kerem. Sharett Institute of oncology, Jerusalem, Not set

Meir Medical Centre, Kefar Sava, Not set

Rabin Medical Centre, Petah Tikva, Not set

Sheba Medical Centre, Ramat Gan, Not set

The Chaim Sheba Medical Center, Ramat Gan, Not set

Kaplan Medical Center, Reẖovot, Not set

Ziv Medical Centre, Safed, Not set

Tel Aviv Sourasky Medical Center, Tel Aviv Yaffo, Not set

Policlinico S. Orsola-Malpighi, Bologna, Not set

Ospedale Cannizzaro, Catania, Not set

AOU Careggi, Firenze, Not set

Ente Ospedaliero Ospedali Galliera, Genova, Not set

IRCCS AOU San Martino, Genova, Not set

ASST Ospedale Alessandro Manzoni, Lecco, Not set

Azienda USL Toscana Nord Ovest Ospedale San Luca, Lucca, Not set

IRST - Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Not set

IRCCS San Raffaele, Milano, Not set

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Not set

Humanitas San Pio X, Milan, Not set

Ospedale di Mirano, Mirano, Not set

Naples, Ist. Naz. Tumori-Fondazione Pascale, Napoli, Not set

AOU di Parma, Parma, Not set

Fondazione IRCCS Policlinico San Matteo, Pavia, Not set

AUSL Piacenza Ospedale Guglielmo da Saliceto, Piacenza, Not set

Nuovo Ospedale di Prato - Santo Stefano, Prato, Not set

AUSL RE Arcispedale Santa Maria Nuova, Reggio Emilia, Not set

AOU Policlinico Umberto I, Roma, Not set

Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Not set

IRCCS Istituto Clinico Humanitas, Rozzano, Not set

National Cancer Center, Goyang, Gyeonggi-do

CHA University - Bundang CHA General Hospital, Seongnam, Gyeonggi-do

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do

Keimyung Dongsan University Hospital, Daegu, Not set

Korea University Anam Hospital, Seoul, Not set

Seoul National University Hospital, Seoul, Not set

Asan Medical Center, Seoul, Not set

Gangnam Severance Hospital, Yonsei University Health System, Seoul, Not set

Samsung Medical Center, Seoul, Not set

The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, Not set

Korea University Guro Hospital, Seoul, Not set

Severance Hospital, Yonsei University Health System, Seoul, Not set

Oslo University Hospital, Radiumhospitalet, Oslo, Not set

Stavanger University Hospital, Stavanger, Not set

University Hospital of North Norway, Tromsø, Not set

The Medical City -Ortigas, Pasig, Metro Manila

Cardinal Santos Medical Center, San Juan, Metro Manila

East Avenue Medical Centre, Quezon City, Not set

Szpitale Pomorskie Sp. z o.o., Gdynia, Not set

Swietokrzyskie Centrum Onkologii, Kielce, Not set

Centrum Badan Klinicznych JCI Jagiellonskie Centrum Innowacji Sp. z o.o., Kraków, Not set

Samodzielny publiczny szpital kliniczny nr 1, Lublin, Not set

Szpital Kliniczny im. Heliodora Swiecickiego, Poznań, Not set

Wielkopolskie Centrum Onkologii, Poznań, Not set

Mazowiecki Szpital Wojewódzki im. sw. Jana Pawla II w Siedlcach Sp. z o.o., Siedlce, Not set

Hospital Universitario Vall d'Hebron, CT Pharm General Building-Floor B, Passeig Vall d'Hebron, Barcelona, Not set

Instituto Catalán de Oncologia, 199-203 Av Gra Via CT Pharmacy, Hospital Duran i Reynals, Barcelona, Not set

Hospital Clinic de Barcelona (Hospital Clinic i Provincial), Barcelona, Not set

Hospital Universitario de A Coruña (CHUAC), Coruña, Not set

Hospital Universitario Reina Sofia, Córdoba, Not set

ICO-Hospital Universitario de Girona, Girona, Not set

Clínica Universidad de Navarra, Madrid, Not set

Hospital La Paz CT Pharmacy, 261 Paseo Castellana, North Building Ground Floor, Madrid, Not set

Hospital Universitario Virgen de la Victoria, Málaga, Not set

Clinica Universitaria Navarra Pamplona, Pamplona, Not set

Hospital Clinico Universitario de Valencia, Valencia, Not set

Karolinska University Hospital, Stockholm, Not set

Uppsala University Hospital, Akademiske Sjukhuset, Uppsala, Not set

Baskent University Hospital, Adana, Not set

Cukurova University Balcali Hospital Application and Research Center, Adana, Not set

Hacettepe University Hospital, Hacettepe Mahallesi, Ankara, Not set

Ankara Baskent University, Ankara, Not set

Istanbul University-Cerrahpasa Medical Faculty Gynecologic Oncology Department, Istanbul, Not set

Ege University Hospital, İzmir, Not set

The Royal Marsden Hospital - Chelsea, Fulham, London

The Royal Marsden Hospital - Sutton, Sutton, Surrey

Singleton Hospital, Swansea, Wales

Cheltenham General Hospital, Cheltenham, Not set

Guy's and St Thomas' NHS Foundation Trust, London, Not set

The Christie / The Christie NHS Foundation Trust, Manchester, Not set

Mount Vernon Cancer Centre East and North Hertfordshire NHS Trust Site, Northwood, Not set

Southampton University NHS Trust, Southampton, Not set

Conditions: Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer

Learn More ›

Using Aspirin to Improve Immunological Features of Ovarian Tumors

NCT05080946

Recruiting

The purpose of the study is to evaluate the effectiveness of aspirin with neoadjuvant chemotherapy for decreasing markers of immune suppression in the tumor at interval debulking surgery, in women with diagnosed ovarian, fallopian tube, or peritoneal carcinoma

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/13/2025

Locations: Moffitt Cancer Center, Tampa, Florida +3 locations

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer

Learn More ›

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

NCT04590326

Recruiting

This study is researching an investigational drug called REGN5668. Participants will receive additional investigational drugs in combination with REGN5668. These additional drugs include cemiplimab or REGN4018 (with or without sarilumab). The main purposes of this study are to: * Learn about the safety and profile of any side effects from the study drugs and to determine the highest, safe dose that can be given to participants with ovarian cancer or cancer of the uterus * Look for signs that t... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/07/2025

Locations: City of Hope Comprehensive Cancer Center, Duarte, California +21 locations

Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, Endometrial Cancer

Learn More ›

A Study of XMT-1660 in Participants With Solid Tumors

NCT05377996

Recruiting

A Study of XMT-1660 in Solid Tumors

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/05/2025

Locations: UC Irvine Health-Chao Family Comprehensive Cancer Center, Orange, California +19 locations

Conditions: Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer, Adenoid Cystic Carcinoma

Learn More ›

CATALINA-2: a Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.

NCT06690775

Recruiting

A Phase 2 study to evaluate the safety and efficacy of TORL-1-23 in patients with advanced ovarian cancer.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

03/04/2025

Locations: SCRI - Arizona Oncology Associates, PC-HOPE, Tucson, Arizona +14 locations

Conditions: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer

Learn More ›

Rinatabart Sesutecan (Rina-S) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

NCT05579366

Recruiting

This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) or cannot be removed with surgery (unresectable).

Gender:

ALL

Ages:

18 years and above

Trial Updated:

03/03/2025

Locations: USOR HonorHealth, Phoenix, Arizona +39 locations

USOR HonorHealth, Phoenix, Arizona

USOR Arizona Oncology Associates, Tucson, Arizona

University of California Los Angeles Medical Center 106, Los Angeles, California

University of California, San Diego; Moores Cancer Center, San Diego, California

USOR Sansum Clinic, Santa Barbara, California

Providence Medical Foundation, Santa Rosa, California

USOR Florida Cancer Specialists South, Fort Myers, Florida

USOR Florida Cancer Specialists North, Saint Petersburg, Florida

USOR Florida Cancer Specialists East, West Palm Beach, Florida

University of Kansas Medical Center (KUMC), Westwood, Kansas

USOR Maryland Oncology Hematology, Rockville, Maryland

Massachusetts General Hospital, Boston, Massachusetts

Dana Farber Cancer Institute, Boston, Massachusetts

Karmanos Cancer Institute, Detroit, Michigan

START Midwest, Grand Rapids, Michigan

USOR Minnesota Oncology Hematology, Maplewood, Minnesota

University of Oklahoma - Health Sciences Center, Oklahoma City, Oklahoma

USOR Oncology Associates of Oregon, P.C., Eugene, Oregon

Compass Oncology - Rose Quarter, Portland, Oregon

Compass Oncology- Rose Quarter, Portland, Oregon

USOR Alliance Cancer Specialist, Doylestown, Pennsylvania

Women and Infants Hospital of Rhode Island, Providence, Rhode Island

Sarah Cannon Research Institute at Tennessee Oncology, Nashville, Tennessee

USOR Texas Oncology, Abilene, Texas

Texas Oncology - Central / South Texas, Austin, Texas

Texas Oncology- Central/South Texas, Austin, Texas

Mary Crowley Cancer Research, Dallas, Texas

USOR Texas Oncology, Fort Worth, Texas

Texas Oncology - Northeast TX, Tyler, Texas

Texas Oncology-Northeast TX, Tyler, Texas

USOR Texas Oncology Gulf Coast, Woodland, Texas

START Mountain Region, West Valley City, Utah

USOR Virginia Cancer Specialists, Fairfax, Virginia

USOR Virginia Oncology Associates, Norfolk, Virginia

Cancer hospital, Chinese Academy of Medical Sciences, Beijing, Beijing

Hunan Cancer Hospital - Phase 1, Changsha, Hunan

Hunan Cancer Hospital - Thoracic Medicine Dept II, Changsha, Hunan

Jilin Cancer Hospital, Chang chun, Jilin

Fudan University Shanghai Cancer Center - Gynecologic Oncology, Shanghai, Shanghai

Fudan University Shanghai Cancer Center- Phase 1, Shanghai, Shanghai

Conditions: Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Non-small Cell Lung Cancer, Mesothelioma, Triple Negative Breast Cancer, High Grade Epithelial Ovarian Cancer, Breast Adenocarcinoma, Hormone Receptor-positive/Her2 Negative Breast Cancer, Platinum-Resistant Ovarian Cancer, Platinum Sensitive Ovarian Cancer (PSOC), High Grade Serous Ovarian Cancer, Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer (NSCLC)

Learn More ›

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

NCT00005095

Recruiting

RATIONALE: To improve strategies for detection and prevention of early-stage disease. PURPOSE: This research study is collecting specimens and data to develop better methods for early detection and prevention of ovarian cancer among the high risk population and those who have the disease.

Gender:

FEMALE

Ages:

Between 18 years and 80 years

Trial Updated:

02/26/2025

Locations: Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago, Illinois

Conditions: Cervical Cancer, Endometrial Cancer, Fallopian Tube Cancer, Hereditary Breast/Ovarian Cancer (brca1, brca2), Ovarian Cancer, Sarcoma, Uterine Leiomyomata, Vaginal Cancer, Vulvar Cancer

Learn More ›

Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)

NCT05281471

Recruiting

The OnPrime study is a multi-center, randomized open-label phase 3 study evaluating the safety and efficacy of Olvi-Vec followed by platinum-doublet chemotherapy and bevacizumab compared to the Active Comparator Arm with Physician's Choice of chemotherapy and bevacizumab in women diagnosed with platinum-resistant/refractory ovarian cancer (includes fallopian tube cancer and primary peritoneal cancer). This Phase III trial builds on the efficacy and safety data reported in the previous Phase II V... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/21/2025

Locations: The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama +29 locations

The University of South Alabama, Mitchell Cancer Institute, Mobile, Alabama

University of Arizona Cancer Center, Tucson, Arizona

City of Hope, Duarte, California

UC San Diego Health - Moores Cancer Center, La Jolla, California

Hoag Gynecologic Oncology, Newport Beach, California

UCI Health Chao Family Comprehensive Cancer Center, Orange, California

AdventHealth Cancer Institute, Orlando, Florida

Sarasota Memorial Research Institute, Sarasota, Florida

Tampa General Hospital/University of South Florida, Tampa, Florida

Women's Cancer Associates with Women's Care Florida, Tampa, Florida

Indiana University Simon Comprehensive Cancer Center, Indianapolis, Indiana

Holy Cross Hospital, Silver Spring, Maryland

University of Michigan, Ann Arbor, Michigan

Karmanos Cancer Institute, Detroit, Michigan

Washington University School of Medicine, Saint Louis, Missouri

Mercy Hospital St. Louis, Saint Louis, Missouri

Women's Cancer Center of Nevada, Las Vegas, Nevada

Center of Hope, Reno, Nevada

Stony Brook Cancer Center, Stony Brook, New York

Levine Cancer Institute, Charlotte, North Carolina

East Carolina University, Greenville, North Carolina

Cleveland Clinic, Cleveland, Ohio

OhioHealth Research Institute, Columbus, Ohio

Kettering Health, Kettering, Ohio

Oklahoma University Health Stephenson Cancer Center, Oklahoma City, Oklahoma

AHN West Penn Hospital, Pittsburgh, Pennsylvania

Hollings Cancer Center, Charleston, South Carolina

Baylor College of Medicine, Houston, Texas

University of Texas Science Center at Houston, McGovern Medical School, Houston, Texas

Providence Sacred Heart Medical Center & Children's Hospital, Spokane, Washington

Conditions: Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer, High-grade Serous Ovarian Cancer, Endometrioid Ovarian Cancer, Ovarian Clear Cell Carcinoma

Learn More ›

First in Human Study of IMGN151 in Recurrent Gynaecological Cancers

NCT05527184

Recruiting

IIMGN151-1001 is a Phase 1, first in human, open-label dose-escalation, optimization, and expansion study designed to characterize the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of IMGN151 in adult participants with recurrent endometrial cancer; recurrent, high-grade serous epithelial ovarian, fallopian tube, and primary peritoneal cancers; or recurrent cervical cancers. All participants will be, in the opinion of the investigator, appropriate... Read More

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/21/2025

Locations: City of Hope National Medical Center /ID# 269036, Duarte, California +15 locations

Conditions: Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cervical Cancer

Learn More ›

An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib

NCT05887609

Recruiting

The Principal Investigator hypothesizes the combination of MIRV and Olaparib is an effective, and tolerable, maintenance therapy strategy in platinum sensitive recurrent ovarian cancer.

Gender:

FEMALE

Ages:

Between 18 years and 100 years

Trial Updated:

02/10/2025

Locations: University of Colorado Hospital, Aurora, Colorado

Conditions: Ovary Cancer, Peritoneal Cancer, Fallopian Tube Cancer

Learn More ›

Study of Senaparib in Combination With Temozolomide in ARID1A Mutation Associated Ovarian Cancer

NCT06617923

Recruiting

This is a phase 2 study to test the effectiveness (anti-tumor activity) of the combination of the study drugs, Senaparib and Temozolomide, in patients with clear cell or endometrioid ovarian cancers that have ARID1A pathologic variants.

Gender:

FEMALE

Ages:

18 years and above

Trial Updated:

02/07/2025

Locations: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland

Conditions: Ovary Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer

Learn More ›

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer

NCT06342986

Recruiting

This is a single center Phase I clinical trial of FT536 administered intraperitoneally (IP) 3 times a week for one week for the treatment of recurrent gynecologic cancers. A short course of outpatient lymphodepleting chemotherapy is given prior to the first dose of FT536 to promote adoptive transfer.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

02/06/2025

Locations: University of Minnesota Masonic Cancer Center, Minneapolis, Minnesota

Conditions: Gynecologic Cancer, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer

Learn More ›

1 - 12 of 31